India, April 1 -- Morepen Laboratories Limited, a global leader in Active Pharmaceutical Ingredient (API) manufacturing, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its anti-allergy API, Loratadine. This milestone marks a significant step in Morepen's strategic expansion into one of the world's largest pharmaceutical markets.
Currently holding an over 80% market share in the US generics market for Loratadine, Morepen has established itself as the leading global manufacturer of the second-generation antihistamine. With more than 25 years of successful exports to the US, the company's API exports are valued at approximately Rs. 650 crores. The Chinese app...